Dear Adherence and Retention Community,
At GHDOnline, we thought it would be nice to get to know each other better as members of this community. So whether you've just joined or been a member of the community for a while, please take a moment to introduce your work and interests to everyone else.
To make things easy, please feel free to use this format:
Populations you work with:
Areas of Interest:
I am an GDHonline member because:
I would like to see more discussion on:
I'll start things off:
Name: Jessica Haberer
Position/Degree: Internist, Research Scientist, Instructor (MD, MS)
Location: Center for Global Health, Massachusetts General Hospital, Boston, MA, USA
Populations: Adults (including serodiscordant couples), children
Areas of Interest: Measurement of ART adherence, ART adherence interventions, HIV prevention with pre-exposure prophylaxis (PrEP), use of mobile technology to measure and support adherence
I am an GDHonline member because: I enjoy learning about diverse viewpoints within this field. It's a wonderful opportunity for members to present their work, ask questions, and get answers. Through my membership, I feel more connected to and aware of the key issues in Adherence and Retention.
I would like to see more discussion on: I am currently very interested in the use of HIV treatment as prevention. For instance, I am concerned that high levels of adherence may be challenging for people with HIV who have not been ill (i.e. those with high CD4 counts). A recent observational study by Adakun et al in JAIDS found that higher CD4 counts (>250) were associated with treatment interruptions and persistent viremia after initiation of ART. It will be important to see more studies in this area, especially as RCTs. How can we support people with high CD4 counts, so that the promising results from HPTN 052 can be realized outside of clinical trial settings? Along similar lines, I am excited about PrEP as a potential prevention method; however, many critics say we should instead focus on treatment as prevention, which is also obviously beneficial for the individual already infected with HIV. I am curious how the A&R Community sees this issue in light of my (and others') concerns about adherence.
The information in this e-mail is intended only for the person to whom it is
addressed. If you believe this e-mail was sent to you in error and the e-mail
contains patient information, please contact the Partners Compliance HelpLine at
http://www.partners.org/complianceline . If the e-mail was sent to you in error
but does not contain patient information, please contact the sender and properly
dispose of the e-mail.